Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study

BACKGROUND: COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala has shown safety, tolerability and efficacy (92·3% [95% CI: 85·7‒95·8]) against SARS-CoV-2 in clinical trials. This study aimed to estimate Abdala's real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Más-Bermejo, Pedro I., Dickinson-Meneses, Félix O., Almenares-Rodríguez, Kenia, Sánchez-Valdés, Lizet, Guinovart-Díaz, Raúl, Vidal-Ledo, María, Galbán-García, Enrique, Olivera-Nodarse, Yadira, Morgado-Vega, Isabel, Dueñas-Carrera, Santiago, Pujol, Merardo, Hernández-Bernal, Francisco, Limonta-Fernández, Miladys, Guillén-Nieto, Gerardo, Muzio-González, Verena L., Ayala-Ávila, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507841/
https://www.ncbi.nlm.nih.gov/pubmed/36185968
http://dx.doi.org/10.1016/j.lana.2022.100366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507841/
https://www.ncbi.nlm.nih.gov/pubmed/36185968
http://dx.doi.org/10.1016/j.lana.2022.100366

Ejemplares similares